psychemedics (nasdaq: pmd) is the world's leading drug testing company using hair for the detection of drugs of abuse. psychemedics has been successfully operating for 30 years and thousands of corporations worldwide currently rely on psychemedics’ patented hair analysis technology for their pre-employment and employee drug screening. psychemedics' clients include over 10% of the fortune 500, some of the largest police departments in america, federal reserve banks, and schools. for more information, visit the psychemedics website at www.psychemedics.com.
Company profile
Ticker
PMD
Exchange
Website
CEO
Raymond C. Kubacki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Psychemedics International, LLC • Psychemedics Laboratórios Ltda • (owned jointly by Psychemedics Corporation • and Psychemedics International ...
IRS number
581701987
PMD stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Mar 24
8-K
Psychemedics Corporation Reports 2023 Financial Results
28 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
27 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Departure of Directors or Certain Officers
8 Nov 23
8-K
Departure of Directors or Certain Officers
22 Sep 23
8-K
Departure of Directors or Certain Officers
31 Aug 23
S-8
Registration of securities for employees
22 Aug 23
Latest ownership filings
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 24
SC 13G/A
KUBACKI RAYMOND C JR
2 Feb 24
4
Daniella Mehalik
24 Jan 24
3
Daniella Mehalik
19 Dec 23
SC 13G
POWELL ANDERSON CAPITAL LP
14 Dec 23
4
Shannon Shoemaker
25 Sep 23
3
Shannon Shoemaker
25 Sep 23
4
Michael Weisenhoff
22 Aug 23
4
Charles M Doucot
21 Aug 23
4
Brian Hullinger
21 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.37 mm | 1.37 mm | 1.37 mm | 1.37 mm | 1.37 mm | 1.37 mm |
Cash burn (monthly) | 358.33 k | 174.00 k | 369.00 k | 243.67 k | 319.33 k | 20.67 k |
Cash used (since last report) | 2.15 mm | 1.04 mm | 2.21 mm | 1.46 mm | 1.91 mm | 123.72 k |
Cash remaining | -775.07 k | 328.39 k | -838.92 k | -88.65 k | -541.61 k | 1.25 mm |
Runway (months of cash) | -2.2 | 1.9 | -2.3 | -0.4 | -1.7 | 60.3 |
Institutional ownership, Q3 2023
25.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 4.05 bn |
Total shares | 1.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
22NW | 274.42 k | $1.09 bn |
Renaissance Technologies | 273.66 k | $1.09 mm |
Vanguard | 251.15 k | $997.07 mm |
RBF Capital | 144.23 k | $572.60 mm |
Ancora Advisors | 78.37 k | $311.14 mm |
BLK Blackrock | 77.38 k | $307.20 mm |
Cannell Capital | 74.79 k | $297.00 k |
Wedbush Securities | 42.41 k | $168.00 k |
Wealth Effects | 40.70 k | $161.58 mm |
Dimensional Fund Advisors | 38.18 k | $151.59 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jan 24 | Daniella Mehalik | Stock Option Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 3.4 | 70,000 | 238.00 k | 70,000 |
22 Jan 24 | Daniella Mehalik | Stock Option Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 3.4 | 35,000 | 119.00 k | 35,000 |
21 Sep 23 | Shannon Shoemaker | Stock Option Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 3.66 | 80,000 | 292.80 k | 80,000 |
21 Sep 23 | Shannon Shoemaker | Stock Option Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 3.66 | 40,000 | 146.40 k | 40,000 |
News
Psychemedics Q4 EPS $(0.86) Down From $(0.12) YoY, Sales $5.00M Down From $5.70M YoY
28 Mar 24
Bearish Sentiment Across The Cannabis Space - Check Full Movers For March 11, 2024
11 Mar 24
Bullish Sentiment Across The Cannabis Space - Check Full Movers For March 8, 2024
8 Mar 24
Cannabis Stock Gainers And Losers From March 7, 2024
7 Mar 24
Cannabis Stock Movers For March 6, 2024
6 Mar 24